CoChat

Targeting dendritic cells to treat multiple sclerosis

Comabella, Manuel, Montalban, Xavier, Münz, Christian, Lünemann, Jan D. · 2010 · Nature Reviews Neurology
Cited by 64

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrneurol.2010.112

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 117

  1. Ben-Nun, A., Wekerle, H. & Cohen, I. R. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11, 195–199 (1981). · DOI · Paper page
  2. Qin, Y. et al. Clonal expansion and somatic hypermutation of VH genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102, 1045–1050 (1998). · DOI · Paper page
  3. Colombo, M. et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J. Immunol. 164, 2782–2789 (2000). · DOI · Paper page
  4. Obermeier, B. et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med. 14, 688–693 (2008). · DOI · Paper page
  5. Meinl, E. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J. Clin. Invest. 92, 2633–2643 (1993). · DOI
  6. Muraro, P. A. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 126, 20–31 (2003). · DOI · Paper page
  7. Skulina, C. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl Acad. Sci. USA 101, 2428–2433 (2004). · DOI · Paper page
  8. Steinman, R. M. Dendritic cells: understanding immunogenicity. Eur. J. Immunol. 37, S53–S60 (2007). · DOI · Paper page
  9. Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685–711 (2003). · DOI · Paper page
  10. Steinman, R. M. & Banchereau, J. Taking dendritic cells into medicine. Nature 449, 419–426 (2007). · DOI · Paper page
  11. Steinman, R. M. Dendritic cells in vivo: a key target for a new vaccine science. Immunity 29, 319–324 (2008). · DOI · Paper page
  12. Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 137, 1142–1162 (1973). · DOI · Paper page
  13. Steinman, R. M. & Cohn, Z. A. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J. Exp. Med. 139, 380–397 (1974). · DOI · Paper page
  14. Yang, L. et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 26, 326–334 (2008). · DOI · Paper page
  15. Nchinda, G. et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 118, 1427–1436 (2008). · DOI · Paper page
  16. Liu, Y. J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23, 275–306 (2005). · DOI · Paper page
  17. Wu, L. & Liu, Y. J. Development of dendritic-cell lineages. Immunity 26, 741–750 (2007). · DOI · Paper page
  18. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107–111 (2007). · DOI · Paper page
  19. Liu, K. et al. In vivo analysis of dendritic cell development and homeostasis. Science 324, 392–397 (2009). · DOI
  20. Fogg, D. K. et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science 311, 83–87 (2006). · DOI · Paper page
  21. Liu, K. et al. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat. Immunol. 8, 578–583 (2007). · DOI · Paper page
  22. D'Amico, A. & Wu, L. The early progenitors of mouse dendritic cells and plasmacytoid predendritic cells are within the bone marrow hemopoietic precursors expressing Flt3. J. Exp. Med. 198, 293–303 (2003). · DOI · Paper page
  23. Karsunky, H. et al. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J. Exp. Med. 198, 305–313 (2003). · DOI · Paper page
  24. Waskow, C. et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 9, 676–683 (2008). · DOI · Paper page
  25. León, B., López-Bravo, M. & Ardavín, C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26, 519–531 (2007). · DOI · Paper page
  26. Shortman, K. & Naik, S. H. Steady-state and inflammatory dendritic-cell development. Nat. Rev. Immunol. 7, 19–30 (2007). · DOI · Paper page
  27. Matyszak, M. K. & Perry, V. H. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 74, 599–608 (1996). · DOI · Paper page
  28. Pashenkov, M. & Link, H. Dendritic cells and immune responses in the central nervous system. Trends Immunol. 23, 69–70 (2002). · DOI
  29. Lande, R. et al. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-β. J. Neuropathol. Exp. Neurol. 67, 388–401 (2008). · DOI
  30. Bulloch, K. et al. CD11c/EYFP transgene illuminates a discrete network of dendritic cells within the embryonic, neonatal, adult, and injured mouse brain. J. Comp. Neurol. 508, 687–710 (2008). · DOI · Paper page
  31. Gottfried-Blackmore, A. et al. Acute in vivo exposure to interferon-γ enables resident brain dendritic cells to become effective antigen presenting cells. Proc. Natl Acad. Sci. USA. 106, 20918–20923 (2009). · DOI · Paper page
  32. Fischer, H. G. & Reichmann, G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. 166, 2717–2726 (2001). · DOI · Paper page
  33. Santambrogio, L. Developmental plasticity of CNS microglia. Proc. Natl Acad. Sci. USA 98, 6295–6300 (2001). · DOI · Paper page
  34. Dittel, B. N. et al. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J. Immunol. 163, 32–39 (1999). · DOI · Paper page
  35. Bailey, S. L. et al. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ TH-17 cells in relapsing EAE. Nat. Immunol. 8, 172–180 (2007). · DOI · Paper page
  36. Khoury, S. J. et al. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J. Exp. Med. 182, 357–366 (1995). · DOI · Paper page
  37. Karni, A. et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J. Immunol. 177, 4196–4202 (2006). · DOI · Paper page
  38. Huang, Y. M. et al. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J. Neuroimmunol. 99, 82–90 (1999). · DOI
  39. Vaknin-Dembinsky, A., Balashov, K. & Weiner, H. L. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol. 176, 7768–7774 (2006). · DOI · Paper page
  40. Stasiolek, M. et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 129, 1293–1305 (2006). · DOI · Paper page
  41. López, C. et al. Altered maturation of circulating dendritic cells in primary progressive MS patients. J. Neuroimmunol. 175, 183–191 (2006). · DOI
  42. Schwab, N. et al. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis. J. Immunol. 184, 5368–5374 (2010). · DOI
  43. Ramgolam, V. S. et al. IFN-β inhibits human Th17 cell differentiation. J. Immunol. 183, 5418–5427 (2009). · DOI · Paper page
  44. Durelli, L. et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β. Ann. Neurol. 65, 499–509 (2009). · DOI · Paper page
  45. Axtell, R. C. et al. T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16, 406–412 (2010). · DOI · Paper page
  46. Comabella, M. et al. A type I interferon signature in monocytes is associated with poor response to interferon-β in multiple sclerosis. Brain 132, 3353–3365 (2009). · DOI · Paper page
  47. Vieira, P. L. et al. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 170, 4483–4488 (2003). · DOI · Paper page
  48. Kim, H. J. et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J. Immunol. 172, 7144–7153 (2004). · DOI · Paper page
  49. Burger, D. et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1β in human monocytes and multiple sclerosis. Proc. Natl Acad. Sci. USA 106, 4355–4359 (2009). · DOI · Paper page
  50. Stüve, O. et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann. Neurol. 59, 743–747 (2006). · DOI · Paper page
  51. del Pilar Martin, M. et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch. Neurol. 65, 1596–1603 (2008). · DOI · Paper page
  52. Matsuki, T. et al. Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis. Int. Immunol. 18, 399–407 (2006). · DOI · Paper page
  53. Cannella, B. & Raine, C. S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37, 424–435 (1995). · DOI · Paper page
  54. Okuda, Y. et al. IL-6 plays a crucial role in the induction phase of myelin oligodendrocyte glucoprotein 35–55 induced experimental autoimmune encephalomyelitis. J. Neuroimmunol. 101, 188–196 (1999). · DOI
  55. Mendel, I. et al. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol. 28, 1727–1737 (1998). · DOI · Paper page
  56. Korn, T. et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA 105, 18460–18465 (2008). · DOI · Paper page
  57. Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987–997 (2008). · DOI · Paper page
  58. Windhagen, A. et al. Expression of costimulatory molecules B7–1 (CD80), B7–2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182, 1985–1996 (1995). · DOI · Paper page
  59. Li, Y. et al. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 130, 490–501 (2007). · DOI · Paper page
  60. Becher, B., Durell, B. G. & Noelle, R. J. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J. Clin. Invest. 112, 1186–1191 (2003). · DOI · Paper page
  61. Cua, D. J., Sherlock, J. & Chen, Y. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744–748 (2003). · DOI · Paper page
  62. Segal, B. M. et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing–remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796–804 (2008). · DOI · Paper page
  63. [No authors listed] TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53, 457–465 (1999). · DOI · Paper page
  64. Vremec, D. et al. The influence of granulocyte/macrophage colony-stimulating factor on dendritic cell levels in mouse lymphoid organs. Eur. J. Immunol. 27, 40–44 (1997). · DOI · Paper page
  65. Salomon, B. & Bluestone, J. A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225–252 (2001). · DOI · Paper page
  66. Bluestone, J. A., St Clair, E. W. & Turka, L. A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24, 233–238 (2006). · DOI · Paper page
  67. Dhodapkar, M. V. et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233–238 (2001). · DOI · Paper page
  68. Weiner, H. L. et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 259, 1321–1324 (1993). · DOI · Paper page
  69. Meyer, A. L. et al. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J. Immunol. 157, 4230–4238 (1996). · DOI
  70. Nicholson, L. B. et al. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3, 397–405 (1995). · DOI · Paper page
  71. Anderton, S. M. et al. Fine specificity of the myelin-reactive T cell repertoire: implications for TCR antagonism in autoimmunity. J. Immunol. 161, 3357–3364 (1998). · DOI
  72. Critchfield, J. M. et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263, 1139–1143 (1994). · DOI · Paper page
  73. Elliott, E. A. et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest. 98, 1602–1612 (1996). · DOI
  74. McFarland, H. I. et al. Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis. J. Immunol. 166, 2116–2121 (2001). · DOI
  75. Lopez-Diego, R. S. & Weiner, H. L. Novel therapeutic strategies for multiple sclerosis—a multifaceted adversary. Nat. Rev. Drug Discov. 7, 909–925 (2008). · DOI
  76. Lutterotti, A., Sospedra, M. & Martin, R. Antigen-specific therapies in MS—Current concepts and novel approaches. J. Neurol. Sci. 274, 18–22 (2008). · DOI
  77. Warren, K. G. et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur. J. Neurol. 13, 887–895 (2006). · DOI
  78. Lobell, A. et al. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med. 187, 1543–1548 (1998). · DOI
  79. Weissert, R. et al. Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen. Proc. Natl Acad. Sci. USA 97, 1689–1694 (2000). · doi:10.1073/pnas.030390097
  80. Bar-Or, A. et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 64, 1407–1415 (2007). · DOI · Paper page
  81. Bielekova, B. et al. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J. Immunol. 172, 3893–3904 (2004). · DOI · Paper page
  82. Kennedy, M. K. et al. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J. Immunol. 145, 117–126 (1990). · DOI
  83. Kennedy, M. K. et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 144, 909–915 (1990). · DOI · Paper page
  84. Tan, L. J. et al. Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance. J. Immunol. 147, 1797–1802 (1991). · doi:10.4049/jimmunol.147.6.1797
  85. Tan, L. J., Kennedy, M. K. & Miller, S. D. Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. J. Immunol. 148, 2748–2755 (1992). · DOI
  86. Menges, M. et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 195, 15–21 (2002). · DOI · Paper page
  87. Trumpfheller, C. et al. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203, 607–617 (2006). · DOI · Paper page
  88. Soares, H. et al. A subset of dendritic cells induces CD4+ T cells to produce IFN-γ by an IL-12-independent but CD70-dependent mechanism in vivo. J. Exp. Med. 204, 1095–1106 (2007). · DOI · Paper page
  89. Nchinda, G. et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 118, 1427–1436 (2008). · DOI · Paper page
  90. Jiang, W. et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375, 151–155 (1995). · DOI · Paper page
  91. Bonifaz, L. et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196, 1627–1638 (2002). · DOI · Paper page
  92. Hawiger, D. et al. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20, 695–705 (2004). · DOI · Paper page
  93. Burgdorf, S. et al. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316, 612–616 (2007). · DOI · Paper page
  94. Tacken, P. J. et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106, 1278–1285 (2005). · DOI · Paper page
  95. Meyer-Wentrup, F. et al. Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood 111, 4245–4253 (2008). · DOI · Paper page
  96. Sancho, D. et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118, 2098–2110 (2008). · DOI · Paper page
  97. Kaden, S. A. et al. Enhanced dendritic cell-induced immune responses mediated by the novel C-type lectin receptor mDCAR1. J. Immunol. 183, 5069–5078 (2009). · DOI
  98. Dzionek, A. et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med. 194, 1823–1834 (2001). · DOI · Paper page
  99. Mukhopadhaya, A. et al. Selective delivery of β cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc. Natl Acad. Sci. USA 105, 6374–6379 (2008). · DOI
  100. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769–779 (2001). · DOI · Paper page
  101. Mahnke, K. et al. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101, 4862–4869 (2003). · DOI · Paper page
  102. Tarbell, K. V. et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204, 191–201 (2007). · DOI · Paper page
  103. Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6, 1176–1182 (2000). · DOI · Paper page
  104. Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6, 1167–1175 (2000). · DOI · Paper page
  105. Piemonti, L. et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J. Immunol. 164, 4443–4451 (2000). · DOI · Paper page
  106. Griffin. M. D. Dendritic cell modulation by 1α, 25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 6800–6805 (2001). · DOI · Paper page
  107. Benkhoucha, M. et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells. Proc. Natl Acad. Sci. USA 107, 6424–6429 (2010). · DOI · Paper page
  108. Rivas-Caicedo, A. et al. Jak3 is involved in dendritic cell maturation and CCR7-dependent migration. PLoS ONE 4, e7066 (2009). · DOI
  109. Walker, J. G. et al. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 992–999 (2007). · DOI
  110. Boy, M. G. et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690, 550 in patients with psoriasis. J. Invest. Dermatol. 129, 2299–2302 (2009). · DOI
  111. Kremer, J. M. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum. 60, 1895–1905 (2009). · DOI · Paper page
  112. Steinman, R. M. & Idoyaga, J. Features of the dendritic cell lineage. Immunol. Rev. 234, 5–17 (2010). · DOI · Paper page
  113. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987–995 (2004). · DOI · Paper page
  114. Münz, C., Steinman, R. M. & Fujii, S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J. Exp. Med. 202, 203–207 (2005). · DOI · Paper page
  115. Serbina, N. V., Jia, T., Hohl, T. M. & Pamer, E. G. Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 26, 421–452 (2008). · DOI · Paper page
  116. Heath, W. R. & Carbone, F. R. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat. Immunol. 10, 1237–1244 (2009). · DOI · Paper page
  117. Robbins, S. H. et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol. 9, R17 (2008). · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Comabella, M., Montalban, X., Münz, C., & Lünemann, J. D.
Venue
Nature Reviews Neurology
Published
2010-08-17
Volume
6
Issue
9
Pages
499-507
ISSN
  • 1759-4758
  • 1759-4766
Cited by
64
References
14
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting dendritic cells to treat multiple sclerosis. https://app.cochat.ai/papers/10.1038/nrneurol.2010.112
The paper
Comabella, M., Montalban, X., Münz, C., & Lünemann, J. D. (2010). Targeting dendritic cells to treat multiple sclerosis. Nature Reviews Neurology. https://doi.org/10.1038/nrneurol.2010.112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.